Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Change in Accured Expenses (2021 - 2025)

Historic Change in Accured Expenses for Abeona Therapeutics (ABEO) over the last 10 years, with Q3 2025 value amounting to $1.0 million.

  • Abeona Therapeutics' Change in Accured Expenses rose 136708.86% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year increase of 27154.77%. This contributed to the annual value of $1.5 million for FY2024, which is 2616.36% down from last year.
  • Latest data reveals that Abeona Therapeutics reported Change in Accured Expenses of $1.0 million as of Q3 2025, which was up 136708.86% from $3.7 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Change in Accured Expenses ranged from a high of $5.3 million in Q4 2021 and a low of -$4.4 million during Q1 2022
  • Its 5-year average for Change in Accured Expenses is $135105.3, with a median of $518000.0 in 2021.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 37818.53% in 2022, then soared by 136708.86% in 2025.
  • Abeona Therapeutics' Change in Accured Expenses (Quarter) stood at $5.3 million in 2021, then crashed by 80.75% to $1.0 million in 2022, then rose by 25.76% to $1.3 million in 2023, then surged by 33.46% to $1.7 million in 2024, then plummeted by 41.36% to $1.0 million in 2025.
  • Its last three reported values are $1.0 million in Q3 2025, $3.7 million for Q2 2025, and -$2.4 million during Q1 2025.